Marvel Biosciences signs letter of intent for Phase 1 trial of MB-204
Tweet Send to a Friend
Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF) has signed a letter of intent with Novatech, a clinical contract research ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




